Earnings summaries and quarterly performance for Amneal Pharmaceuticals.
Executive leadership at Amneal Pharmaceuticals.
Chintu Patel
Detailed
Co-Chief Executive Officer
CEO
Chirag Patel
Detailed
Co-Chief Executive Officer and President
CEO
AK
Anastasios Konidaris
Detailed
Executive Vice President, Chief Financial Officer
AB
Andrew Boyer
Detailed
Executive Vice President, Chief Commercial Officer-Generics
JD
Jason Daly
Detailed
Executive Vice President, Chief Legal Officer and Corporate Secretary
NS
Nikita Shah
Detailed
Executive Vice President, Chief Human Resources Officer
Board of directors at Amneal Pharmaceuticals.
Research analysts who have asked questions during Amneal Pharmaceuticals earnings calls.
David Amsellem
Piper Sandler Companies
4 questions for AMRX
Also covers: ABBV, ALKS, AMGN +27 more
LS
Leszek Sulewski
Truist Securities
4 questions for AMRX
Also covers: AKBA, ANIP, BHC +6 more
CS
Christopher Schott
JPMorgan Chase & Co.
3 questions for AMRX
Also covers: ABBV, AMGN, BIIB +15 more
BP
Balaji Prasad
Barclays
2 questions for AMRX
Also covers: ALVO, ELAN, LGND +7 more
CS
Chris Stott
JPMorgan Chase & Co.
1 question for AMRX
MD
Matthew Dellatorre
Goldman Sachs Group Inc.
1 question for AMRX
Also covers: INCY, TEVA
Recent press releases and 8-K filings for AMRX.
Amneal and mAbxience Receive FDA Approval for Denosumab Biosimilars
AMRX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- The U.S. Food and Drug Administration (FDA) has approved Boncresa and Oziltus, two denosumab biosimilars referencing Prolia and XGEVA, with Amneal holding exclusive U.S. commercialization rights and mAbxience handling development and manufacturing.
- These approvals increase Amneal's commercial biosimilar portfolio to five, with plans to expand to six by 2027, targeting a market that generated approximately $5.3 billion in U.S. sales over the last 12 months for the reference products.
- Investors and analysts view these approvals as a growth catalyst for Amneal's specialty portfolio, aligning with management's strategic emphasis on the biosimilars market.
- Amneal reported approximately $2.93 billion in revenue and a market capitalization of nearly $4.03 billion, though financial metrics present a mixed picture, including valuation concerns and noted insider selling despite solid operational liquidity.
Dec 22, 2025, 9:39 PM
Amneal Discusses Business Diversification, Growth in Injectables and Biosimilars, and CREXONT Projections
AMRX
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Amneal Pharmaceuticals has completed a financial turnaround and diversified its business, shifting focus from oral solid generics to higher-growth areas like specialty, biosimilars, and injectables.
- The company anticipates its generic injectables revenue to grow from approximately $200 million this year to $240-$250 million next year, with plans to add around 10 new products annually to its current portfolio of 40 products.
- Amneal expects its biosimilars revenue to reach about $100 million this year, with a pipeline of five new biosimilars launching through 2026-2028, including a significant $4 billion generic XOLAIR opportunity projected for 2027.
- The specialty product CREXONT for Parkinson's disease is projected to generate $60 million in revenue this year and $120 million next year, with a long-term annual revenue goal of $300-$500 million.
- Amneal has invested in R&D and manufacturing capabilities for GLP-1s, including two new manufacturing sites in India, positioning the company for future participation in these markets.
Dec 3, 2025, 2:30 PM
Amneal Discusses Diversification, Growth in Generics, Biosimilars, and Specialty Portfolio at Piper Sandler Conference
AMRX
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Amneal's CFO, Tasos Konidaris, outlined the company's diversification strategy, including a significant shift in its affordable medicines business by de-emphasizing oral solid generics (down from 53% to a projected 10%-15% of revenue) and focusing on complex generics.
- The company anticipates its generic injectables revenue to grow from approximately $200 million this year to $240-$250 million next year, supported by a portfolio of 40 products and an annual addition of about 10 new products.
- Amneal's biosimilars segment, which generated no revenue three years ago, is projected to reach $100 million in revenue this year, with a pipeline including a 2027 opportunity for generic Xolair, a $4 billion market that could yield hundreds of millions of dollars for Amneal.
- The specialty drug Crexont, for Parkinson's, is expected to generate approximately $60 million in revenue this year, projected to grow to $120 million next year, with a long-term target of $300-$500 million in annual revenue.
- Amneal has made substantial investments in R&D and manufacturing capabilities for GLP-1s and complex peptides, including two new manufacturing sites in India, positioning the company for future participation in these markets.
Dec 3, 2025, 2:30 PM
Amneal (AMRX) Outlines Diversification Strategy and Growth Projections for Injectables, Biosimilars, and Specialty Products
AMRX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Amneal (AMRX) is strategically shifting its business focus away from oral solid generics, which comprised 25% of revenue last year and are projected to decrease to 10%-15% in the coming years, towards complex generics, biosimilars, and injectables. This shift is supported by 90% of its R&D pipeline being dedicated to complex generics.
- The company projects significant growth in its injectables and biosimilars segments; injectables revenue is expected to increase from $200 million this year to $240-$250 million next year, while biosimilars revenue is anticipated to reach $100 million this year. Key future opportunities include the Omnipaque generic starting in 2026 and the Xolair biosimilar in 2027, targeting a $4 billion market.
- Amneal's specialty product Crexont, for Parkinson's patients, is demonstrating strong performance, with projected revenues of $60 million this year and $120 million next year, with a long-term goal of $300-$500 million in annual revenue. Payer access for Crexont is expected to reach 70% next year.
- The company has launched a DHE auto-injector, projecting $10-$15 million in revenue for 2026 and a long-term potential of $50-$100 million. Additionally, Amneal is investing in GLP-1s and complex peptides, including building an auto-injector facility in India capable of producing 100 million units per year, positioning for future market entry.
Dec 3, 2025, 2:30 PM
Amneal Pharmaceuticals Receives FDA Approval for Iohexol Injection
AMRX
Product Launch
- Amneal Pharmaceuticals, Inc. (AMRX) has received U.S. FDA approval for its iohexol injection (300 mg Iodine/mL), marking it as the first generic version of GE Healthcare's Omnipaque® (iohexol) injection.
- The company expects to launch the product in the first quarter of 2026.
- U.S. annual sales for iohexol injection, the reference product, were approximately $652 million for the 12 months ended September 2025.
- This approval reinforces Amneal's leadership in differentiated, complex injectables and its commitment to improving access to high-quality, affordable medicines.
Nov 13, 2025, 9:01 PM
Achieve Life Sciences Reports Q3 2025 Financial Results and Key Regulatory Milestones
AMRX
Earnings
Product Launch
Management Change
- Achieve Life Sciences reported a net loss of $14.4 million for the third quarter of 2025 and $40.0 million for the nine months ended September 30, 2025.
- The company held $48.1 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
- The FDA accepted the New Drug Application (NDA) for cytisinicline for smoking cessation, with a Prescription Drug User Fee Act (PDUFA) targeted action date of June 20, 2026.
- Achieve was awarded the FDA Commissioner's National Priority Voucher for cytisinicline for e-cigarette or vaping cessation, being one of only nine therapies to receive this inaugural designation.
- Erik Atkisson was appointed as Chief Legal Officer in October.
Nov 6, 2025, 12:00 PM
Amneal Pharmaceuticals (AMRX) Reports Q3 2025 Results and Updates Full-Year Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals (AMRX) reported Q3 2025 revenue of $785 million, an increase of 12%, with adjusted EBITDA of $160 million (+1%) and adjusted EPS of $0.17 (+6%).
- The company updated its full-year 2025 guidance, projecting adjusted EBITDA between $675 million and $685 million and adjusted EPS of $0.75 to $0.80.
- All three segments demonstrated revenue growth in Q3 2025, with Specialty and Affordable Medicines each growing 8%, and AvKARE growing 24%.
- Key growth drivers include continued strong uptake of CREXONT® for Parkinson's disease, which is currently treating approximately 17,000 U.S. patients, and the launch of Brekiya® DHE autoinjector for migraine and cluster headache.
- Amneal completed a successful debt refinancing, which is expected to lower interest costs and extend maturities from 2028 to 2032.
Oct 30, 2025, 12:30 PM
Amneal Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported Q3 2025 revenues of $785 million, a 12% year-over-year increase, and adjusted EBITDA of $160 million, growing 1% compared to the prior year.
- The company raised its full-year 2025 adjusted EBITDA guidance to a new range of $675 million to $685 million and adjusted EPS guidance to $0.75 to $0.80.
- Key growth drivers include strong performance in the Specialty segment, with Crexant expected to achieve peak U.S. sales of $300 million-$500 million, and the launch of the Brachia autoinjector.
- In the Affordable Medicines segment, Amneal has launched 17 new products in 2024 and has 69 ANDAs pending, with 64% being complex products.
- Amneal submitted its Biologics License Application (BLA) for biosimilar Xolair, targeting a U.S. market over $4 billion, and aims to have six marketed biosimilar products by 2027.
Oct 30, 2025, 12:30 PM
Amneal Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals reported Q3 2025 revenues of $785 million and adjusted EBITDA of $160 million, marking 12% and 1% year-over-year growth, respectively, with adjusted EPS at $0.17. Year-to-date, total revenue increased 7%, adjusted EBITDA grew 9%, and adjusted EPS grew 35%.
- The company raised its full-year 2025 adjusted EBITDA guidance to a new range of $675 million to $685 million and adjusted EPS guidance to $0.75 to $0.80, while maintaining revenue guidance at $3 billion to $3.1 billion.
- Key growth drivers include the successful launch of the Brachia autoinjector for migraine and cluster headache and strong performance from Crexant, which has a peak U.S. sales potential of $300 million to $500 million.
- Amneal is advancing its GLP-1 collaboration with Metsera and made significant progress in biosimilars, including submitting its BLA for biosimilar Xolair and aiming for six marketed biosimilar products by 2027.
- The Affordable Medicines segment continues to grow with 17 new product launches in 2024 and a robust pipeline of 69 pending ANDAs, 64% of which are complex products. The company also strengthened its balance sheet, reducing net leverage to 3.7 times.
Oct 30, 2025, 12:30 PM
Amneal Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates Full Year Guidance
AMRX
Earnings
Guidance Update
Product Launch
- Amneal Pharmaceuticals, Inc. reported net revenue of $785 million for the third quarter of 2025, an increase of 12% compared to the third quarter of 2024.
- For Q3 2025, the company reported GAAP net income of $2 million and diluted income per share of $0.01. Adjusted EBITDA was $160 million and adjusted diluted EPS was $0.17.
- Revenue growth was driven by an 8% increase in Specialty net revenue from key branded products, an 8% increase in Affordable Medicines net revenue from complex product portfolio and new launches, and a 24% increase in AvKARE net revenue from government label sales.
- The company updated its 2025 full-year guidance, maintaining net revenue at $3.0 billion - $3.1 billion, raising Adjusted EBITDA to $675 million - $685 million, and increasing Adjusted diluted EPS to $0.75 - $0.80.
Oct 30, 2025, 10:19 AM
Quarterly earnings call transcripts for Amneal Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more